Psychiatry Research
Volume 125, Issue 2 , Pages 81-86 , 15 February 2004

Once-daily high-dose pindolol for SSRI-refractory depression

  • Kenneth N. Sokolski

      Affiliations

    • VA Long Beach Healthcare System, 5901 East 7th Street (06/116a), Long Beach, CA 90822, USA
    • University of California Irvine Medical Center, 101 The City Drive South, Orange, CA 92868, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-562-826-8000x2848; fax: +1-562-826-5088
    • ,
  • Janet C. Conney

      Affiliations

    • VA Long Beach Healthcare System, 5901 East 7th Street (06/116a), Long Beach, CA 90822, USA
    • ,
  • Brenda J. Brown

      Affiliations

    • VA Long Beach Healthcare System, 5901 East 7th Street (06/116a), Long Beach, CA 90822, USA
    • ,
  • Edward M. DeMet

      Affiliations

    • VA Long Beach Healthcare System, 5901 East 7th Street (06/116a), Long Beach, CA 90822, USA
    • University of California Irvine Medical Center, 101 The City Drive South, Orange, CA 92868, USA

Received 17 March 2003 ,Revised 23 September 2003 ,Accepted 16 December 2003.

References 

  1. Berman RM, Anand A, Cappiello A, Miller HL, Hu XS, Oren DA, et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biological Psychiatry. 1999;45:1170–1177
  2. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. Journal of Clinical Psychopharmacology. 1995;15:217–222
  3. Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. Journal of Clinical Psychiatry. 1998;59(Suppl 5):16–23
  4. Dursun SM, Devarajan S, Kutcher S. ‘The Dalhousie serotonin cocktail’ for treatment-resistant major depressive disorder. Journal of Psychopharmacology. 2001;15:136–138
  5. Kornbluh R, Papakostas GI, Petersen T, Neault NB, Nierenberg AA, Rosenbaum JF, et al. A survey of prescribing preferences in the treatment of refractory depression: recent trends. Psychopharmacology Bulletin. 2001;35:150–156
  6. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol in major depression. Journal of Affective Disorders. 1996;41:210–210
  7. Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. Journal of Clinical Psychopharmacology. 1999;19:177–182
  8. Martinez D, Broft A, Laruelle M. Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies. Biological Psychiatry. 2000;48:844–853
  9. Martinez D, Mawlawi O, Huang D, Kent J, Simpson N, Parsey R, et al. Positron emission tomography study of pindolol occupancy of 5-HT1A receptors in humans: preliminary analyses. Nuclear Medicine and Biology. 2000;27:523–527
  10. McAskill R, Mir S, Taylor D. Pindolol augmentation of antidepressant therapy. British Journal of Psychiatry. 1998;173:203–208
  11. Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Canadian Journal of Psychiatry. 2000;45:476–481
  12. Moreno FA, Gelenberg AJ, Bachar K, Gelgado PL. Pindolol augmentation of treatment-resistant depressed patients. Journal of Clinical Psychiatry. 1997;58:437–439
  13. Olver JS, Cryan JF, Burrows GD, Norman TR. Pindolol augmentation of antidepressants: a review and rationale. Australia and New Zealand Journal of Psychiatry. 2000;34:71–79
  14. Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double-blind randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Archives of General Psychiatry. 1999;56:375–379
  15. Perez V, Puigdemont D, Gilaberte I, Alvarez E, Artigas F. Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical pharmacokinetic, and methodological factors. Journal of Clinical Psychopharmacology. 2001;21:36–45
  16. Pineyro G, Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacology Review. 1999;51:533–591
  17. Puzantian T, Kawase K. Does the addition of pindolol accelerate or enhance the response to selective serotonin reuptake inhibitor antidepressants?. Pharmacotherapy. 1999;19:205–212
  18. Rabiner EA, Gunn RN, Castro ME, Sargent PA, Cowen PJ, Koepp MJ, et al. β-blocker binding to human 5-HT1A receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology. 2000;23:285–293
  19. Rabiner EA, Bhagwagar Z, Gunn RN, Sargent PA, Bench CJ, Cowen PJ, et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. American Journal of Psychiatry. 2001;158:2080–2082
  20. Rudd P. Partial compliance: implications for clinical practice. Journal of Cardiovascular Pharmacology. 1993;22(Suppl A):S1–S5
  21. Spitzer RL, Williams JBW, Gibbon W, First MB. Structured Clinical Interview for DSM-IV. Washington, DC: American Psychiatric Press; 1995;
  22. Thase ME, Rush AJ. Treatment-resistant depression. In:  Bloom FE,  Kupfer DJ editor. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995;p. 1081–1098

PII: S0165-1781(03)00303-2

doi: 10.1016/j.psychres.2003.12.006

Psychiatry Research
Volume 125, Issue 2 , Pages 81-86 , 15 February 2004

Article Tools

* Image Usage & Resolution